Philip J Broadhurst1, Andrew R Hart2,3. 1. Norwich Medical School, University of East Anglia, Norwich, NR4 7TJ, UK. pbroadhurst@doctors.org.uk. 2. Norwich Medical School, University of East Anglia, Norwich, NR4 7TJ, UK. 3. Norfolk and Norwich University Hospital NHS Trust, Norwich, NR4 7TJ, UK.
Abstract
PURPOSE:Metformin has plausible direct and indirect anti-cancer properties against pancreatic adenocarcinoma cells. However, metformin may only be efficacious in patients with inoperable pancreatic ductal adenocarcinoma (PDAC) without liver metastases. Absorption may be decreased by gastrointestinal symptoms and proton pump inhibitors (PPIs). We aimed to justify and inform a future phase III trial of metformin versus placebo on survival in inoperable PDAC by documenting prevalence of patients meeting eligibility criteria, gastrointestinal symptoms and PPI use. METHODS:Patient notes with PDAC were reviewed at a large teaching hospital over 2 years. Study variables were obtained from multiple sources of information. RESULTS: 141 participants were identified (51.8% female), of which 37.6% were not prescribed metformin at diagnosis and had no radiological hepatic metastases. Characteristics were similar between non-metformin and metformin users. In eligible patients, 65.2% reported nausea and vomiting and 46.2% were prescribed PPIs. CONCLUSION: Approximately, a third of all patients with inoperable PDAC are eligible for a future trial of metformin, allowing an estimate of the number of hospitals required for recruitment. Nausea and vomiting are common and should be managed effectively to prevent trial dropouts. PPI use is frequent and their influence on metformin's pharmacodynamic actions needs to be clarified.
RCT Entities:
PURPOSE:Metformin has plausible direct and indirect anti-cancer properties against pancreatic adenocarcinoma cells. However, metformin may only be efficacious in patients with inoperable pancreatic ductal adenocarcinoma (PDAC) without liver metastases. Absorption may be decreased by gastrointestinal symptoms and proton pump inhibitors (PPIs). We aimed to justify and inform a future phase III trial of metformin versus placebo on survival in inoperable PDAC by documenting prevalence of patients meeting eligibility criteria, gastrointestinal symptoms and PPI use. METHODS:Patient notes with PDAC were reviewed at a large teaching hospital over 2 years. Study variables were obtained from multiple sources of information. RESULTS: 141 participants were identified (51.8% female), of which 37.6% were not prescribed metformin at diagnosis and had no radiological hepatic metastases. Characteristics were similar between non-metformin and metformin users. In eligible patients, 65.2% reported nausea and vomiting and 46.2% were prescribed PPIs. CONCLUSION: Approximately, a third of all patients with inoperable PDAC are eligible for a future trial of metformin, allowing an estimate of the number of hospitals required for recruitment. Nausea and vomiting are common and should be managed effectively to prevent trial dropouts. PPI use is frequent and their influence on metformin's pharmacodynamic actions needs to be clarified.
Entities:
Keywords:
Drug absorption; Metformin; Pancreatic cancer; Trial eligibility
Authors: G Zhou; J Yu; A Wang; S-H Liu; J Sinnett-Smith; J Wu; R Sanchez; J Nemunaitis; C Ricordi; E Rozengurt; F C Brunicardi Journal: Curr Mol Med Date: 2016 Impact factor: 2.222
Authors: Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux Journal: N Engl J Med Date: 2011-05-12 Impact factor: 91.245
Authors: Sil Kordes; Michael N Pollak; Aeilko H Zwinderman; Ron A Mathôt; Mariëtte J Weterman; Aart Beeker; Cornelis J Punt; Dick J Richel; Johanna W Wilmink Journal: Lancet Oncol Date: 2015-06-08 Impact factor: 41.316
Authors: Jan Holger Rothe; Christian Grieser; Lukas Lehmkuhl; Dirk Schnapauff; Carmen Perez Fernandez; Martin H Maurer; Axel Mussler; Bernd Hamm; Timm Denecke; Ingo G Steffen Journal: Eur J Radiol Date: 2012-06-19 Impact factor: 3.528
Authors: Chikako Suzuki; Hans Jacobsson; Thomas Hatschek; Michael R Torkzad; Katarina Bodén; Yvonne Eriksson-Alm; Elisabeth Berg; Hirofumi Fujii; Atsushi Kubo; Lennart Blomqvist Journal: Radiographics Date: 2008 Mar-Apr Impact factor: 5.333
Authors: Fernanda D Gonzalez-Guindalini; Marcos P F Botelho; Carla B Harmath; Kumaresan Sandrasegaran; Frank H Miller; Riad Salem; Vahid Yaghmai Journal: Radiographics Date: 2013-10 Impact factor: 5.333
Authors: Anne T Nies; Ute Hofmann; Claudia Resch; Elke Schaeffeler; Maria Rius; Matthias Schwab Journal: PLoS One Date: 2011-07-14 Impact factor: 3.240
Authors: Kaixin Zhou; Celine Bellenguez; Chris C A Spencer; Amanda J Bennett; Ruth L Coleman; Roger Tavendale; Simon A Hawley; Louise A Donnelly; Chris Schofield; Christopher J Groves; Lindsay Burch; Fiona Carr; Amy Strange; Colin Freeman; Jenefer M Blackwell; Elvira Bramon; Matthew A Brown; Juan P Casas; Aiden Corvin; Nicholas Craddock; Panos Deloukas; Serge Dronov; Audrey Duncanson; Sarah Edkins; Emma Gray; Sarah Hunt; Janusz Jankowski; Cordelia Langford; Hugh S Markus; Christopher G Mathew; Robert Plomin; Anna Rautanen; Stephen J Sawcer; Nilesh J Samani; Richard Trembath; Ananth C Viswanathan; Nicholas W Wood; Lorna W Harries; Andrew T Hattersley; Alex S F Doney; Helen Colhoun; Andrew D Morris; Calum Sutherland; D Grahame Hardie; Leena Peltonen; Mark I McCarthy; Rury R Holman; Colin N A Palmer; Peter Donnelly; Ewan R Pearson Journal: Nat Genet Date: 2010-12-26 Impact factor: 38.330